Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2451 capsule pharmacokinetics study in healthy adults
NL-OMON45502Phase 1Withdrawn
- Sponsor
- Galapagos NV
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLPG2451 in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoints: Pharmacokinetics of GLPG2451 and Safety and tolerability of GLPG2451. Planned start Apr 2017; status: withdrawn.
02
Drugs
GLPG2451
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45502.